Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.48/Shre
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.69 +3.07%
EPS Growth %: -266.7%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
CIX, ARIS, COHR, More
EPS Growth %: -266.7%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
CIX, ARIS, COHR, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.48), versus ($0.09) reported last year. Revenue for the quarter came in at $2.9 million versus the consensus estimate of $679 thousand.
- Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development
- First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter
- Continued Progress in the Commercialization of alfataliglicerase in Brazil
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- NewAmsterdam Pharma Company N.V. (NAMS) Tops Q3 EPS by 35c
- FatPipe, Inc. (FATN) Reports Q3 EPS of $0.09
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
